Page last updated: 2024-12-08
bw 58c
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 146797 |
| CHEMBL ID | 4524847 |
| SCHEMBL ID | 1151720 |
| SCHEMBL ID | 1542903 |
| SCHEMBL ID | 917366 |
| SCHEMBL ID | 13832378 |
| MeSH ID | M0131108 |
Synonyms (29)
| Synonym |
|---|
| bw 58c |
| trans-2-(4-(1,1-dimethylethyl)cyclohexyl)-3-hydroxy-1,4-naphthalenedione |
| 1,4-naphthalenedione, 2-(4-(1,1-dimethylethyl)cyclohexyl)-3-hydroxy- |
| 2-(4'-t-butylcyclohexyl)-3-hydroxy-1,4-naphthoquinone |
| 2-(4-tert-butylcyclohexyl)-3-hydroxy-1,4-naphthoquinone |
| 58c80 |
| 2-(4-(1,1-dimethylethyl)cyclohexyl)-3-hydroxy-1,4-naphthalenedione |
| 1,4-naphthalenedione, 2-(4-(1,1-dimethylethyl)cyclohexyl)-3-hydroxy-, trans- |
| 3-(4-tert-butylcyclohexyl)-4-hydroxynaphthalene-1,2-dione |
| 94015-46-0 |
| bw-a 58c |
| 86790-29-6 |
| bupravaquone |
| SCHEMBL1151720 |
| cis 2-(4'-t-butylcyclohexyl)-3-hydroxy-1,4-naphthoquinone |
| NWCVRXADYNRXCT-BETUJISGSA-N |
| cis-2-hydroxy-3-(4-t-butylcyclohexyl)-1,4-naphthquinone |
| cis-2-(4-t-butylcyclohexyl)-3-hydroxy-1,4-naphthquinone |
| NWCVRXADYNRXCT-UHFFFAOYSA-N |
| SCHEMBL1542903 |
| SCHEMBL917366 |
| SCHEMBL13832378 |
| NWCVRXADYNRXCT-JOCQHMNTSA-N |
| trans-2-hydroxy-3-(4-t-butylcyclohexyl)-1,4-naphthquinone |
| CHEMBL4524847 |
| 2-(4-t-butylcyclohexyl)-3-hydroxy-1,4-naphthoquinone |
| DB06740 |
| 2-[4-(1,1-dimethylethyl)cyclohexyl]-3-hydroxy-1,4-naphthalenedione |
| DTXSID80916695 |
Research Excerpts
Dosage Studied
| Excerpt | Relevance | Reference |
|---|---|---|
| "Kidneys from male and female Wistar rats dosed with 1 of 3 chemically unrelated pharmacological agents, a pyrazoline BW540C, a naphthoquinone BW58C and the levoisomer of tetramisole, levamisole or the light hydrocarbon Decalin, were examined by light and electron microscopy." | ( Induction and exacerbation of hyaline droplet formation in the proximal tubular cells of the kidneys from male rats receiving a variety of pharmacological agents. Astbury, PJ; Morgan, RJ; Parsons, DN; Port, CJ; Read, NG, 1988) | 0.27 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Research
Studies (6)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 3 (50.00) | 18.7374 |
| 1990's | 3 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 20.12
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (20.12) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 1 (16.67%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (83.33%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||